August 5, 2003

News Release: Novamex USA intends to acquire a Patent used to develop a Test for Mad Cow Disease

Novamex USA Ltd. (Pink Sheets: NOVM) is pleased to announce its intention to acquire the worldwide patent no. PCT/FR 02/00728 which covers testing for a protein (prion).

Ville Saint-Laurent, Que (PRWEB) August 04, 2003 - Novamex USA Ltd. (Pink Sheets: NOVM) is pleased to announce its intention to acquire the worldwide patent no. PCT/FR 02/00728 which covers testing for a protein (prion). This unique testing method was used to develop a test for Bovine Spongiform Encephalopathy also known as ‘’Mad Cow Disease’’ which can be performed on living animals. If completed, Novamex USA Ltd. will issue 6,000,000 common shares of the company and make a payment of $50,000 USD, to the developers and patent holders, Dr. Louis Lery and Dr. Jacques A. Mayet, for the acquisition of the worldwide patent no. PCT/FR 02/00728. Upon completion of the transaction both Dr. Léry and Dr. Mayet will be joining the Board of Directors of Novamex.

Closing of this transaction is subject to mutual due diligence to be completed on or before September 02, 2003.

ABOUT THE ACQUISITION:

Dr. Louis Léry and Dr. Jacques A. Mayet have patented a unique test to detect Prions in blood. The first application for the test is a diagnostic blood test performed on living animals on site to detect Bovine Spongiform Encephalopathy (BSE) also known as ‘’Mad Cow Disease’’. A second application of the pre mortem Prion test under development is to test for the new variant form of Creutzfeldt-Jakob Disease (CJD) in humans.

Dr. Léry and Dr. Mayet have validated the user-friendly, pre mortem diagnostic test, after four years of research and expect to release a commercially ready BSE diagnostic test kit within 11 to 15 months, followed by CJD products in the future.

ABOUT NOVAMEX USA LTD:

NOVAMEX is a development stage biotechnology company, incorporated in the state of Oregon, working in the field of rapid diagnostic tests using immunodetection specifically for agri-food and veterinary applications. The company is listed on the Pink Sheets under the symbol NOVM.

DISCLAIMER:

This PRESS RELEASE contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which act contains a safe harbor for forward looking statements. Statements made in connection with initial public offerings, however, are not protected by the safe harbor of the Private Securities Litigation Reform Act of 1995. Nonetheless, the Company believes that investors would be benefitted by the cautionary language included in this paragraph. For this purpose any statements contained in this PRESS RELEASE that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "estimate," or "continue" or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within the Company's control. These factors include but are not limited to economic conditions generally and in the industries in which the Company may participate; competition within the Company's chosen industry, including competition from much larger competitors; technological advances and failure by the Company to successfully develop business relationships.

Contact: Karim Menassa, President
This email address is being protected from spambots. You need JavaScript enabled to view it.

EMAIL